Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane F Apperley

Showing results (31-40 of 195) with videos related to

Pageof 20
Sort By:
Blood|December 13, 2006
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioningCharles Crawley, Simona Iacobelli, Bo Björkstrand, et al.
Haematologica|July 28, 2006
Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemiaJolanta B Perz, Jamshid S Khorashad, David Marin, et al.
American Journal of Hematology|June 11, 2020
Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13)Andrew Hastings, Jane F Apperley, Elisabet Nadal-Melsio, et al.
Leukemia Research|August 6, 2005
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to BortezomibMarianna Politou, Anastasios Karadimitris, Evangelos Terpos, et al.
Blood|June 4, 2005
Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatmentBeate Schultheis, Richard Szydlo, François X Mahon, et al.
Thyroid : Official Journal of the American Thyroid Association|March 18, 2015
Thyroid function abnormalities associated with ponatinib therapy in patients with chronic myeloid leukemiaRenuka Palani, Jane F Apperley, Alistair Reid, et al.
Annals of Hematology|July 18, 2024
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemiaJeffrey H Lipton, Tim H Brümmendorf, Kendra Sweet, et al.
Blood|April 26, 2003
Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of responseEdward D Seaton, Richard M Szydlo, Edward Kanfer, et al.
Haematologica|February 27, 2003
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylateDavid Marin, Sarah Marktel, Nicola Foot, et al.
British Journal of Haematology|September 27, 2003
Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myelomaEvangelos Terpos, Marianna Politou, Richard Szydlo, et al.
Pageof 20

Showing results (31-40 of 195) with videos related to

Sort By:
Pageof 20
Blood|December 13, 2006
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioningCharles Crawley, Simona Iacobelli, Bo Björkstrand, et al.
Haematologica|July 28, 2006
Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemiaJolanta B Perz, Jamshid S Khorashad, David Marin, et al.
American Journal of Hematology|June 11, 2020
Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13)Andrew Hastings, Jane F Apperley, Elisabet Nadal-Melsio, et al.
Leukemia Research|August 6, 2005
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to BortezomibMarianna Politou, Anastasios Karadimitris, Evangelos Terpos, et al.
Blood|June 4, 2005
Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatmentBeate Schultheis, Richard Szydlo, François X Mahon, et al.
Thyroid : Official Journal of the American Thyroid Association|March 18, 2015
Thyroid function abnormalities associated with ponatinib therapy in patients with chronic myeloid leukemiaRenuka Palani, Jane F Apperley, Alistair Reid, et al.
Annals of Hematology|July 18, 2024
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemiaJeffrey H Lipton, Tim H Brümmendorf, Kendra Sweet, et al.
Blood|April 26, 2003
Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of responseEdward D Seaton, Richard M Szydlo, Edward Kanfer, et al.
Haematologica|February 27, 2003
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylateDavid Marin, Sarah Marktel, Nicola Foot, et al.
British Journal of Haematology|September 27, 2003
Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myelomaEvangelos Terpos, Marianna Politou, Richard Szydlo, et al.
Pageof 20